Tampa

The trials here

What the 11 trials at this site are about, from their registry records.

Conditions

• Depression6 trials
• Schizophrenia6 trials
• Bipolar disorder2 trials
• Friedreich ataxia1 trial

Phase

• Phase 37 trials
• Phase 42 trials
• Phase 11 trial
• Phase 21 trial

Status

• Recruiting6 trials
• Completed2 trials
• Not yet recruiting1 trial
• Terminated1 trial
• Withdrawn1 trial

Lead sponsor

• Neurocrine Biosciences11 trials

Running trials

• Not yet recruiting

  Study of NBIB-223 Gene Therapy in Friedreich's Ataxia (FACET)

  NCT07934303· Phase 1· Neurocrine Biosciences· Source

• Recruiting

  Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

  NCT07227818· Phase 3· Neurocrine Biosciences· Source

• Recruiting

  A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

  NCT07105111· Phase 4· Neurocrine Biosciences· Source

• Recruiting

  A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  NCT07196501· Phase 3· Neurocrine Biosciences· Source

• Recruiting

  NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

  NCT07114874· Phase 3· Neurocrine Biosciences· Source

• Recruiting

  Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  NCT06966401· Phase 3· Neurocrine Biosciences· Source

• Recruiting

  NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  NCT06911112· Phase 3· Neurocrine Biosciences· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Depression4 recruiting
• Schizophrenia3 recruiting
• Bipolar disorder1 recruiting
• Friedreich ataxia1 recruiting

Closed trials

• Recruiting

  NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  NCT06963021· Phase 3· Neurocrine Biosciences· Source

• Completed

  Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia

  NCT05859698· Phase 4· Neurocrine Biosciences· Source

• Terminated

  Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia

  NCT05182476· Phase 2· Neurocrine Biosciences· Source

• Completed

  Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia

  NCT05110157· Phase 3· Neurocrine Biosciences· Source